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aims: Cognitive decline disproportionately affects older adult type 2 diabetes. We tested 
whether randomized intensive (INT) glucose-lowering reduces the rate(s) of cognitive 
decline in adults with advanced type 2 diabetes (mean: age, 60 years; diabetes duration, 
11 years) from the Veterans Affairs Diabetes Trial.
Methods: A battery of neuropsychological tests [digit span, digit symbol substitution 
(DSym), and Trails-making Test-Part B (TMT-B)] was administered at baseline in ~1700 
participants and repeated at year 5. Thirty-seven risk factors were evaluated as predic-
tors of cognitive decline in multivariable regression analyses.
results: The mean age-adjusted DSym or TMT-B declined significantly in all study 
participants (P < 0.001). Randomized INT glucose-lowering did not significantly alter 
the rate of cognitive decline. The final model of risk factors associated with 5-year 
decline in age-adjusted TMT-B included as significant predictors: longer baseline dia-
betes duration (beta = −0.028; P = 0.0057), lower baseline diastolic blood pressure 
(BP; beta = 0.028; P = 0.002), and baseline calcium channel blocker medication use 
(beta = −0.639; P <  0.001). Higher baseline pulse pressure was significantly asso-
ciated with decline in age-adjusted TMT-B suggesting a role for both higher systolic 
and lower diastolic BPs. Baseline thiazide diuretic use (beta = −0.549; P =  0.015) 
was an additional significant predictor of 5-year decline in age-adjusted digit symbol 
score. Post-baseline systolic BP-lowering was significantly associated (P < 0.001) with 
decline in TMT-B performance. There was a significant inverse association between 
post-baseline plasma  triglyceride-lowering (P =  0.045) and decline in digit symbol 
substitution task performance.
conclusion: A 5-year period of randomized INT glucose-lowering did not significantly 
reduce the rate of cognitive decline in older-aged adults with type 2 diabetes. Systolic 
and diastolic BPs as well as plasma triglycerides appeared as modifiable risk factors of 
the rate of cognitive decline in older adult type 2 diabetes.
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inTrODUcTiOn
Diabetes is associated with a twofold increased risk for age-related 
cognitive decline or dementia (1, 2). Increasing life expectancy 
and the current global epidemic of type 2 diabetes mellitus 
(T2DM) (3) may cause a sharp increase in the numbers of older 
T2DM adults suffering with cognitive impairment or dementia 
(4) during the next several decades. Yet the key risk factors and 
underlying mechanisms contributing to accelerated cognitive 
aging in adult T2DM remain largely undefined. Type 2 diabetes 
and age-related cognitive decline share several underlying risk 
factors, including obesity, hypertension, and hyperlipidemia. 
Yet, few clinical trials have addressed whether randomization to 
intensive (INT) glycemic control may slow the rate of cognitive 
decline (5). The Veterans Affairs Diabetes Trial (VADT) rand-
omized 1791 older adults with T2DM to standard (STD) or INT 
glycemic treatment (6). Similar desirable mean blood pressure 
(BP) and lipid levels were achieved in the majority of STD- or 
INT-treated participants (6). After an average of 6 years of study 
treatment, the primary VADT cardiovascular disease (CVD) 
outcome did not differ significantly according to original ran-
domized glycemic treatment assignment (6). The current study 
is from a planned secondary analysis to the VADT designed to 
test whether INT glycemic treatment slows cognitive decline in 
older adult T2DM. All study participants underwent a battery of 
neuropsychological tests to assess cognitive function in several 
overlapping domains, e.g., working memory, processing speed, 
and executive function. The neuropsychological tests, digit span 
(DS), digit symbol substitution task (DSym), and Trails-making 
Test-Part B (TMT-B) were administered at baseline and again at 
the year 5 study visit in all available participants.
sUBJecTs anD MeThODs
study Participants
The study design and clinical inclusion and exclusion criteria 
for the main VADT have been previously reported (6). Written 
informed consent to the local IRB-approved protocol was pro-
vided by all participants at each of the 20 participating study 
sites. Eligible patients without significant renal insufficiency or 
congestive heart failure were randomly assigned to STD vs. INT 
glycemic treatment. All participants were older than 40 years, and 
96% were men. Among 1791 randomized participants, 1678 com-
pleted all three neuropsychological tests at baseline. One hundred 
thirty-six participants had terminated study participation prior 
to year 5, and did not undergo repeat neuropsychological testing. 
An additional three hundred eighty-three participants did not 
undergo repeat (year 5) neuropsychological testing. Participants 
who were lost to year 5 neuropsychological testing follow-up did 
not differ significantly in their baseline age, systolic or diastolic 
BP, or randomized glycemic study treatment assignment com-
pared to those who completed year 5 testing. Participants who 
were lost to neuropsychological follow-up testing had slightly 
longer baseline duration of diabetes (12.0 vs. 11.3 years) and a 
higher percentage had experienced a prior CVD event at baseline 
study entry (44 vs. 38%; P = 0.014) compared to participants who 
completed both baseline and year 5 neuropsychological testing.
Medications
As previously reported, all patients were receiving antidiabetic 
medications at baseline study entry, including oral agents and/
or insulin (6). Randomized glycemic treatment in the STD 
or INT arms involved the use of similar classes of antidiabetic 
medications, but at different doses. The thiazolidinedione (TZD) 
rosiglitazone was prescribed for most patients randomized to 
INT treatment. Baseline anti-hypertensive medication classes 
included angiotensin-converting enzyme (ACE) inhibitors, 
angiotensin receptor blockers (ARBs), calcium channel blockers 
(CCB), and thiazide diuretics.
Blood Pressure and laboratory Measures
Blood pressure was recorded in study clinics while patients were 
seated and after allowing a 5-min period of rest. The median value 
of the three consecutive determinations, computed separately 
for systolic and diastolic BPs, was used for analysis. Laboratory 
measures, including urinary microalbumin, plasma hemoglobin 
A1c, urine creatinine, plasma total cholesterol, triglycerides, and 
high-density lipoprotein (HDL) cholesterol, were determined by 
standardized methods, as previously described (6).
neuropsychological Test Measures
Three standardized neuropsychological tests were administered 
at baseline and repeated at the year 5 study visit for all able, 
available VADT study participants. The tests were DS and 
digit symbol (DSym) subtests, both from The Wechsler Adult 
Intelligence Scale-III (7), and the TMT-B (8, 9). These three 
tests collectively are neurocognitive measures of auditory and 
visual attention, concentration, mental control, short-term audi-
tory memory, verbal working memory, verbal memory span, 
cognitive processing speed, cognitive flexibility, task switching, 
sequencing, spatial organization, visual pursuit, and executive 
cognitive function. For the DS test, the subject listens to a string 
of verbally presented numbers, then repeats them back. The dif-
ficulty increases as the digit string lengthens. The digits have no 
logical relationship to each other. DS Forward requires a repeti-
tion of the number sequence exactly as presented; DS Backwards 
requires the number sequence to be repeated in reverse order 
(e.g., response for “1-8-3-7” is “7-3-8-1”). The test is discontin-
ued when two repetition attempts are failed at a particular string 
length (e.g., six digits cannot be repeated correctly). The longest 
string length successfully repeated is then recorded as the final 
score. DS Forward and DS Backwards scores are summed to a 
final DS raw score. DS measures short-term auditory memory, 
attention, concentration, and working memory. Verbal work-
ing memory is necessary for everyday tasks involving recall of 
sequences of information (e.g., telephone numbers, understand-
ing long and complex sentences).
DSym is a matching-to-sample task where key symbols are 
uniquely associated with a number from 1 to 9. An 8.5 ×  11″ 
response page presents a row of boxes showing the symbol–num-
ber combinations to be used as the reference for the task. Below 
the reference key row is a practice sample, followed by rows of 
boxes containing a number, with a blank area to write in the asso-
ciated symbol. The test is timed; the goal is to complete as many 
TaBle 1 | Baseline clinical characteristics in study subjects by randomized 
treatment.
sTD inT P-value
Education
Less than high 
school
29 36 0.39
Some high school 63 68 0.66
GED or high 
school graduate
255 265 0.66
Vocational or 
technical school
43 47 0.67
Some college 322 293 0.24
College graduate 116 105 0.46
Some graduate 
school
18 22 0.53
Graduate/
professional degree
50 56 0.56
Total 896 892
Scaled digit span 10.18 ± 3.04 (n = 887) 10.16 ± 2.99 (n = 877) 0.92
Scaled digit symbol 8.84 ± 3.34 (n = 886) 8.75 ± 3.28 (n = 873) 0.58
Scaled Trails B 8.60 ± 2.31 (n = 844) 8.74 ± 2.30 (n = 834) 0.21
STD (standard), INT (intensive) glycemic treatment.
Results are N (for Education level) or mean ± SD (for scaled cognitive test scores).
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symbol–number combinations as possible before time expires. 
Higher scores are associated with better working memory, 
strategy/planning, psychomotor competence, visual scanning, 
and efficiency of new learning. DSym is a multi-factorial test 
that is sensitive to decreased cognitive functioning secondary to 
changes in brain functioning.
Trails-making Test-Part B involves drawing, with a pencil 
on paper, a trail between 25, encircled numbers and letters that 
are randomly distributed across the 8.5  ×  11″ response page 
(“connect-the-dots”). TMT-B requires that the subject alternate 
between numbers and letters (i.e., draw a line from 1 to A, A to 
2, 2 to B, etc.) as quickly as possible without making sequenc-
ing errors. The test is timed and the final score represents the 
amount of time required to draw a line connecting all 25 circles. 
TMT-B is also a multi-factorial test that is sensitive to decreased 
cognitive functioning secondary to changes in brain function-
ing. For each neuropsychological test, the individual raw score 
was transformed to an age-specific, scaled score using published 
normative tables (7, 10).
Change in scaled neurocognitive test scores was calculated 
as the difference between year 5 and baseline scaled scores. 
A negative value for the difference is indicative of a decline 
in cognitive test performance. Since higher raw score in the 
TMT-B (seconds required for completion) is indicative of worse 
cognitive performance, transformation of the TMT-B raw score 
to a scaled score involves the use of an inverse scaling factor. 
Post-baseline risk factor change (e.g., systolic BP) was calculated 
as the difference between the year 5 and baseline mean level. 
Raw cognitive test scores that appeared as significant outliers, 
e.g., DS >  30 or DSym >  133, were considered as unreliable 
and treated as missing data. In several patients who were either 
unable to hold a pen/pencil, or had severe visual impairment, 
i.e., were legally-blind, the TMT-B raw score (>300  s) was 
treated as missing data. The neuropsychological test data were 
continually monitored by VA Cooperative Study Coordinating 
Center staff during the study trial, and lay staff at all study sites 
were provided with additional training in the administration 
of neuropsychological test battery at regularly scheduled study 
meetings.
statistics
Multivariable regression analysis was used to model the asso-
ciation between baseline risk factors and the 5-year change in 
scaled DS, digit symbol, or TMT-B. Thirty-seven potential risk 
factors grouped according to their relatedness, e.g., demographic 
(race, ethnicity, age, gender, education level), anthropometric 
(weight, BMI, waist–hip ratio, height), atherosclerosis (smoking, 
systolic or diastolic BP, total cholesterol, LDL cholesterol, HDL 
cholesterol, triglycerides), thrombosis (baseline aspirin use, 
PAI-1, fibrinogen), medical co-morbidities (hypertension, prior 
CVD event, nephropathy, serum creatinine, microalbuminuria), 
glucose-lowering medications (insulin, sulfonylureas, TZD, 
metformin), BP-lowering medications (CCB, thiazide diuretic, 
ACE inhibitor or ARB), lipid-lowering medications (statins, 
fibrates, fish oil) or diabetes-specific variables (diabetes duration, 
any hypoglycemia, any post-baseline, or severe post-baseline 
hypoglycemia) were evaluated (in multivariable regression 
analysis) for association with 5-year change in scaled cognitive 
test score(s). Risk variable(s) significantly or nearly significantly 
(P < 0.10) associated with 5-year change in age-adjusted, scaled 
cognitive test score(s) were included (together with randomized 
glycemic treatment group) as covariates in final regression mod-
eling of risk factors associated with change in cognitive test score. 
Backward elimination was used to obtain the best-fit model using 
an α level of less than 0.05 as the cutoff for variable retention in 
the final model.
resUlTs
Baseline scaled cognitive Test score(s) by 
randomized Treatment assignment
Baseline clinical characteristics previously reported in the study 
population did not differ significantly by randomized glycemic 
treatment group, including mean (SD): age 60.4 (8.7) years, body 
mass index 31.3 (3.5) kg/m2, hemoglobin A1c 9.4 (2.0)%, diabetes 
duration 11.4 (7.5) years, systolic BP 132 (17) mmHg, diastolic BP 
76 (10) mmHg, or total cholesterol concentration 184 (47) mg/
dL (6). Forty percent of patients reported a prior cardiovascular 
event, 72% had baseline hypertension, and 17% of participants 
were current smokers at baseline study entry (6). There was no 
significant difference in baseline educational attainment in study 
participants randomized to STD vs. INT glycemic treatment 
(Table  1). There was no significant difference in the baseline 
scaled DS, digit symbol substitution, or TMT-B score in patients 
assigned to STD or INT glycemic control (Table 1).
Five-Year change in scaled cognitive 
Test scores
We next computed the mean (and 95% confidence intervals) for 
the scaled DS, digit symbol, and Trails B test scores obtained 
at baseline and repeated at the 5-year study visit by a subset of 
TaBle 2 | Mean change in 5-year scaled cognitive test score.
Test Baseline Year 5 Mean changea 95% ci N P-value^
Digit span 10.279 10.277 −0.003 −0.153 to 0.148 1174 NS
Digit symbol 8.995 8.080 −0.92 −1.086 to −0.745 1155 <0.001
Trails B 8.703 8.226 −0.48 −0.622 to −0.331 1114 <0.001
aChange is (Year 5 – baseline) scaled score, NS, not significant.
^P-value from T-test, compared to no change.
N = 1174 (Digit span), N = 1155 (Digit symbol), N = 1114 (Trails B).
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all participants (Table  2). There was no significant difference 
(−0.003) in the mean scaled DS score (between the baseline and 
the 5-year interval measurement) in participants who completed 
the DS at both study intervals (Table 2). The mean scaled digit 
symbol score declined significantly (−0.92; P < 0.001, Table 2) 
and the mean scaled TMT-B declined significantly (−0.488; 
P <  0.001, Table  2) between the baseline and 5-year interval 
measurements. These results are consistent with Yeung et al. (11) 
who reported that executive function (Trails B) and processing 
speed (digit symbol) were affected by type 2 diabetes to a signifi-
cantly greater extent than was recall. The distribution of change 
in scaled cognitive test score in all study participants perfor-
mance by randomized treatment assignment group is illustrated 
in Figures  1A–C. There were no significant differences in the 
mean change (over the 5-year period) in scaled DS (Figure 1A, 
P = 0.83), scaled digit symbol (Figure 1B, P = 0.97) or scaled 
TMT-B (Figure  1C, P =  0.55) test score between participants 
randomized to intensive (INT) vs. STD glycemic treatment.
association between groups of related 
risk Factors and 5-Year cognitive Decline
There was no significant association between 5-year change in 
any of the three cognitive tests and the following baseline risk 
variables: body mass index, waist–hip ratio, gender, smoking, 
education, serum creatinine, microalbuminuria, plasma total 
cholesterol, LDL cholesterol, HDL cholesterol or triglyceride 
concentration, any baseline hypoglycemia, (any or severe) 
post-baseline hypoglycemia, baseline use of insulin, TZD, ACE 
inhibitor, ARBs, or fish oil medication. In nested, multivariable 
regression analyses that tested groups of related variables, higher 
baseline systolic BP, higher baseline pulse pressure, higher plasma 
fibrinogen, baseline aspirin use, baseline metformin use, baseline 
history of prior CVD event was each significantly associated 
with 5-year decline in TMT-B score (Table S1 in Supplementary 
Material). Baseline aspirin or sulfonylurea use was significantly 
or inversely significantly associated, respectively, with the rate of 
decline in scaled DSym test score (Table S2 in Supplementary 
Material). There was a non-significant trend (P =  0.068) of an 
association between baseline statin use and 5-year decline in 
Trails making B test score (Table S1 in Supplementary Material), 
a non-significant trend (P =  0.071) of an association between 
baseline statin use and 5-year decline in DS test score (not 
shown in Supplementary Material) and a non-significant 
trend (P  =  0.075) of an association between baseline fibrate 
use and 5-year improvement in DSym test soccer (Table S2 in 
Supplementary Material).
Final Model of risk Factors associated 
with Decline in cognitive Test 
Performance
The final model of risk factors associated with 5-year decline in 
scaled DS test performance included as significant predictors: 
African-American race (P <  0.001), and baseline thiazide diu-
retic use (P =  0.036) (Table 3). The final model of risk factors 
associated with 5-year decline in scaled TMT-B included as 
significant predictors: diabetes duration (P =  0.006), diastolic 
BP (P = 0.002), and baseline CCB medication use (P < 0.001) 
(Table 3). The final model of risk factors associated with 5-year 
decline in scaled digit symbol substitution task included as sig-
nificant predictors: diabetes duration (P = 0.034), baseline CCB 
medication use (P =  0.011), and baseline thiazide diuretic use 
(P = 0.015) (Table 3).
association between Post-Baseline risk 
Factors and Decline in cognitive Test 
Performance
Post-baseline systolic BP-lowering was significantly associated 
(P < 0.001) with decline in TMT-B performance (Table 4); and 
post-baseline diastolic BP-lowering was significantly inversely 
associated (P  =  0.003) with decline in TMT-B performance 
(Table 4). Post-baseline pulse pressure-lowering was significantly 
associated (P  <  0.001) with decline in TMT-B performance 
(Table 4). There was a significant inverse association between post-
baseline plasma triglyceride-lowering (P = 0.045) and decline in 
digit symbol substitution task performance (Table 4). There were 
no significant associations between post-baseline plasma total 
cholesterol-lowering and 5-year decline in DS (P = 0.536), DSym 
(P = 0.706), or TMT-B (P = 0.244) test performance.
DiscUssiOn
The current findings are the first to suggest that a 5-year period 
of INT glucose-lowering did not significantly slow the rate of 
cognitive decline experienced by older adult male veterans with 
T2DM. These findings are in agreement with results from the 
ACCORD-MIND study in which three and one-third years of 
randomized INT glucose-lowering did not substantially alter the 
trajectory of cognitive decline in older adult men and women 
with advanced type 2 diabetes (5). Since 5–6 years of randomized 
INT glucose-lowering (in the VADT) did not significantly reduce 
cardiovascular event occurrence (6) or alter the rate of cognitive 
decline, these data do not support INT glucose-lowering as a 
FigUre 1 | continued
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TaBle 4 | association between post-baseline modifiable risk factor level 
and change in scaled cognitive test performance.
Parameter estimate se P-value
(a) Trails B
Change in syst BP (mmHg) 0.018 0.0050 <0.001
Change in dias BP (mmHg) −0.026 0.0086 0.003
(B) Trails B
Change in pulse press (mmHg) 0.018 0.0051 <0.001
(c) Digit symbol
Change in plasma
Triglyceride (mg/dL) −0.0013 0.00064 0.045
(A) N = 1106.
(B) N = 1109.
(C) N = 1147; syst(olic), dias(tolic) blood press(ure).
TaBle 3 | Final model of risk factors associated with 5-year decline 
in (a) digit span, (B) Trails-making Part B, and (c) digit symbol test 
performance.
Parameter estimate se P-value
(a) Digit span
Treatment (INT vs. STD) −0.026 0.153 0.863
African-American (yes/no) −0.807 0.209 <0.001
Thiazide diuretic (yes/no) −0.425 0.202 0.036
(B) Trails B
Treatment (INT vs. STD) 0.0024 0.147 0.987
Diabetes duration (years) −0.028 0.010 0.006
Diastolic BP (mmHg) 0.028 0.0091 0.002
CCB (yes/no) −0.639 0.184 <0.001
(c) Digit symbol
Treatment (INT vs. STD) 0.067 0.172 0.697
Diabetes duration (years) −0.025 0.012 0.034
CCB (yes/no) −0.557 0.217 0.011
Thiazide diuretic (yes/no) −0.549 0.225 0.015
(A) N = 1159.
(B) N = 1099; BP, blood pressure; CCB-calcium channel blocker.
(C) N = 1139.
FigUre 1 | Box–whisker plot of the distribution of 5-year change in (a) digit span, (B) Trails making Test-Part B, or (c) Digit symbol age-adjusted test 
score in standard vs. intensive glucose-lowering treatment groups. (a–c) P-value(s) from T-test comparing mean scaled score in standard vs. intensive 
glucose-lowering treatment group. Boxes represent first and third quartiles, horizontal line denotes median value, whiskers represent minimum and maximum values. 
(a) N = 1174; (B) N = 1155; (c) N = 1114.
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primary therapeutic approach to slowing cognitive decline in 
older adult men with advanced T2DM.
Prior studies have suggested a long-lasting legacy effect of 
midlife systolic BP elevation on the rate of cognitive decline 
among older, non-diabetic adults (12, 13). The present finding 
of significant associations between baseline systolic BP, baseline 
pulse pressure or the baseline use of specific anti-hypertensive 
medication classes, and accelerated rate(s) of decline in working 
memory, processing speed, and executive function are consistent 
with a long-lasting “legacy” effect from elevated systolic BP or 
elevated pulse pressure on the promotion of accelerated cognitive 
decline in adult T2DM. CCB and thiazide diuretics are known 
to substantially lower systolic BP (14) and were likely used (in 
the VADT) principally as add-on medications in patients having 
difficult-to-control or refractory baseline hypertension. In sup-
port of this possibility, African-American patients who are prone 
7Zimering et al. Cognitive Decline in Adult Diabetes
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to higher rate(s) of systolic hypertension were significantly more 
likely to have experienced a decline in working memory (scaled DS 
test score) compared to non-Hispanic white or Hispanic patients.
Systolic hypertension is characterized by elevated systolic and 
decreased diastolic BP leading to a widened pulse pressure, i.e., 
the difference between systolic and diastolic BPs. Systolic hyper-
tension frequently accompanies normal aging (15) and is thought 
to be due at least (in part) to age-related, loss of elastic recoil 
in large arteries (15). The biologic mechanisms underlying an 
association between systolic hypertension and accelerated cogni-
tive decline in older adult advanced type 2 diabetes are largely 
unexplored and beyond the scope of the present study. Yet results 
from previous longitudinal studies conducted in non-diabetic 
populations (15–17) suggest that elevated systolic BP (even in 
young adults) correlated with white matter and gray matter brain 
structural changes that are early markers of decreased cogni-
tive performance (18, 19). One possible mechanism by which 
increased arterial stiffness may contribute to cognitive decline 
is via excessive mechanical force applied to vascular endothelial 
cells. Studies in animal models or in  vitro cell systems suggest 
that endothelial dysfunction resulting from excessive mechani-
cal force causes altered expression of proteases (20), increased 
vascular permeability (21), or increased endothelial adherence 
and transmigration of inflammatory cells (22).
Our data suggest an important vascular component to the 
risk for cognitive impairment in older adult diabetes, 72% of 
whom had baseline hypertension. For example, in our prelimi-
nary multivariable regression analyses, several traditional risk 
factors associated with stroke and CVD (e.g., baseline aspirin 
use, plasma fibrinogen) were associated with accelerated rates of 
decline in processing speed and executive function. Our finding 
that baseline duration of diabetes was a strong, significant predic-
tor of accelerated decline(s) in processing speed and executive 
function is consistent with results from other studies (23, 24). 
We were unable to demonstrate a significant association between 
any or serious, post-baseline hypoglycemia and accelerated rate 
of cognitive decline among VADT participants. Even though 
the total number of hypoglycemia episodes was substantially 
increased in the INT treatment group, relatively few INT- vs. 
STD-treated patients (8.5 vs. 3.1%) experienced documented 
serious hypoglycemia (6).
The current data suggest a complex relationship between 
post-baseline BP-lowering and the rate of decline in executive 
function. According to our regression model, each 10  mmHg 
reduction in post-baseline systolic BP (or pulse pressure) was 
associated with an 18% decline in scaled TMT-B score. In a 
VADT patient who was 60 years or older at baseline study entry, 
an 18% decline in age-adjusted TMT-B score would correspond 
to advancing cognitive age by ~4 years. Our model predicts that 
post-baseline diastolic BP-lowering was simultaneously protec-
tive against decline in scaled TMT-B score and that maintaining 
an adequate pulse pressure (during randomized treatment) could 
mitigate against accelerated cognitive decline. Of interest, the 
mean pulse pressure in VADT patients assigned to STD or INT 
glycemic treatment was roughly 56 mmHg both at baseline and 
at the year 6 follow-up visit (6). Several large randomized clinical 
trials in non-diabetic populations suggest that, when aggressive 
systolic BP-lowering was undertaken in older-age hypertensive 
adults, it did not translate into a consistent reduction in the 
rate of occurrence of either dementia or substantial cognitive 
impairment (25). In the ACCORD study of older adult T2DM, 
INT BP-lowering that targeted systolic BP to a level less than 
120 mmHg was associated with significant reduction(s) in total 
brain volume without an observable effect on the rate of cognitive 
decline (26). Taken together with the present findings, these results 
suggest that overly aggressive therapeutic systolic BP-lowering 
should not be undertaken without compensatory reduction in 
diastolic BP. Cerebral autoregulation normally ensures constant 
cerebral blood flow in the setting of declining systolic BP via 
changes in local brain arteriolar resistance. It is possible, however, 
that excessive therapeutic narrowing of the pulse pressure may 
lead to non-pulsatile blood flow that is known to predispose to 
accelerated atherosclerosis (27) and microvascular endothelial 
dysfunction (28).
Our novel finding that post-baseline plasma triglyceride-low-
ering was associated with a significant protection against decline 
in cognitive processing speed suggests an additional important 
modifiable risk factor for slowing accelerated cognitive aging in 
T2DM. In our regression model, each 50  mg/dL reduction in 
plasma triglycerides was associated with a corresponding 6.5% 
improvement in digit symbol substitution scaled score. Based 
on age-specific DSym normative values, a 6.5% improvement in 
DSS scaled score is predicted to have had an effect equivalent to 
delaying cognitive aging by nearly 4 years among higher baseline-
functioning patients who were 65  years or older at baseline 
VADT randomization. Of interest, VADT patients randomized 
to INT or STD treatment experienced mean reductions in plasma 
triglyceride level of 50 mg/dL (INT) or 64 mg/dL, respectively 
(6) consistent with an overall cognitive benefit from randomized 
VADT treatment. By contrast, in the ACCORD study of INT 
lipid-lowering, three and one-third years of randomized fibrate 
treatment alone did not significantly alter the rates of decline in 
processing speed (DSS) or in total brain volume (26). More study 
is needed to determine whether a longer treatment period (60 
vs. 40  months), higher baseline mean plasma triglyceride level 
(213 vs. 162 mg/dL), or larger post-baseline reduction in mean 
plasma triglyceride level (57 vs. 30 mg/dL) in VADT participants 
vs. ACCORD lipid-lowering study participants may have contrib-
uted to differences in cognitive study outcomes between the two 
clinical trials. Epidemiologic data support an association between 
higher triglyceride level and the incidence of ischemic stroke (29) 
that may also contribute to cognitive decline in high-risk older 
diabetic populations. Although INT glucose-lowering per se did 
not alter the rate of cognitive decline in the VADT, substantial and 
sustained glucose-lowering experienced by both INT- and STD-
treated VADT patients may have translated to beneficial slowing 
of the rate of cognitive decline (in part) via its known favorable 
effects on very-low-density-lipoprotein metabolism (30).
Our study findings are applicable to older men (mean age 
60.4  years) with advanced T2DM (mean duration 11.4  years), 
highly prevalent hypertension and underlying CVD, i.e., 40% of 
participants reported a prior CVD event at baseline study entry 
(6). Strengths of our study included the long treatment interval 
between baseline and follow-up cognitive performance tests that 
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not only maximized the chance of detecting a true biological 
change in cognition among individual study participants, but 
also minimized the possibility of bias due to a “practice effect” 
on test performance results, as reported for the TMT-B (10). 
A limitation of our study is the lack of generalizability of the 
findings to women who are known to experience a higher rate 
of age-associated dementia or severe cognitive decline (4). The 
effect(s) of post-baseline BP- or triglyceride-lowering on rate(s) 
of change in cognitive function must be interpreted with cau-
tion since they were derived from post hoc exploratory analyses. 
More randomized study is needed to validate these results and 
determine optimal treatment targets for systolic BP, diastolic BP, 
pulse pressure, or plasma triglycerides associated with delaying 
the rate of accelerated cognitive aging in older adult T2DM.
Statins are among the most widely prescribed medications 
having proven benefit in reducing cardiovascular event occur-
rence in middle-aged and older diabetic and non-diabetic 
populations (31). Recent concerns about statin intolerance (31) 
have been focused (in part) on reports of statin-induced cognitive 
dysfunction (32). Yet few data exist in vulnerable older adult type 
2 diabetic populations regarding a possible relationship between 
statin use and accelerated cognitive decline. The present study 
was not specifically designed to evaluate the effect of statins 
on cognitive function. Although the borderline significant 
associations between baseline statin use and accelerated 5-year 
decline(s) in executive function and recall are of interest, they 
do not necessarily imply causality. Rather they likely reflect 
confounding by indication, i.e., higher baseline prevalence(s) 
of coronary and cerebrovascular atherosclerotic disease among 
baseline statin-users. Several recent reports suggest that large-
vessel cerebrovascular atherosclerosis, e.g., carotid stenosis, 
alters cerebral hemodynamics resulting in declines in cognitive 
function (33, 34). Carotid stenosis interacted significantly with 
impaired cerebral microvascular reactivity (which increases in 
diabetes) (34) leading to significantly greater declines in execu-
tive function, memory, and attention (33, 34).
In summary, our novel findings add to accumulating evidence 
suggesting that INT glucose-lowering alone should not be under-
taken solely for the purpose of reducing the rate of cognitive 
decline in older-aged adults with type 2 diabetes. Our preliminary 
results are the first to suggest that systolic BP-lowering, when it 
is undertaken in older-age individuals (compared to in midlife), 
has complex effects on the rate of cognitive decline, but that taken 
together with attention to plasma triglyceride-lowering may 
provide fruitful avenue(s) for future research aimed at slowing 
the rate of decline in processing speed (and preserving independ-
ence) in older adult T2DM.
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